

## **HIV/TB Co-infection project**

### **Instructions for TB form**

**NOTE: Please read these “Instructions” and “List of definitions of TB diagnosis and treatment outcomes” carefully before you complete the forms. Please use black ink when filling out the form.**

**TB Enrolment and Follow-up forms should be completed for all HIV-infected patients diagnosed with TB at your clinic since 01.01.2011. Please notice that information on HIV infection should be collected on a separate form (HIV infection form). In case you already have data on HIV infection electronically in your database, please contact us at [hivtb@cphiv.dk](mailto:hivtb@cphiv.dk) for electronic data-exchange.**

1. In general, complete these forms either by writing “X”, by filling out a numeric field, or by completing the information regarding the day, month, and year for time-variables. If the month is unknown, write only the year. If the month and year are both unknown, write “02/79”.
2. Please provide Centre or Cohort name. Please assign a number to each patient according to the patient log (decodification list) taking the numbers in sequence.
  - If a patient is part of any cohort, please provide the existing number within this cohort in addition to the HIV/TB number.

Please make sure to keep a decoding list with patients’ names and numbers in order.

#### **3. Section A: Information on background demographics:**

- All questions should be completed. Please provide risk factors for TB acquisition, if “travelling in endemic area”, please specify where. Please indicate the patient’s origin, especially if the his or her origin is not the country of residence.
- For IDUs please provide information on whether the patient is currently an active IDU or receiving substitution therapy.
- The most recently measured weight should be entered. Please try to collect this parameter on as many patients as possible (also during follow-up).
- Height should also be entered, if available.

#### **4. Section B: Information regarding previous TB diagnosis (should only be filled out if a patient has had TB in the past):**

- Previous TB diagnosis should be considered as any case of TB in the past, and the patient should not be on TB treatment for at least 2 months at the date of current TB case. If the patient has more than one TB diagnosis in the past, please fill out the most recent (to the current TB) episode.
- Please indicate the date when the last TB treatment was stopped
- Information should also be given on what the treatment outcome of previous TB was (definitions of treatment outcome are available at the end of the instruction on page 3).
- Please indicate all drugs used for treatment of previous TB and the results of resistance tests (if any).

#### **5. Section C: Contains information regarding the current case of TB:**

- The date of the current TB diagnosis is either the date when a specimen positive for *Mycobacterium tuberculosis* was obtained, or the date when anti-TB treatment was initiated, whichever comes first.

## **HIV/TB Co-infection project**

### **Instructions for TB form**

- Information regarding Isoniazid or any other chemoprophylaxis up to the date of current diagnosis is kindly requested.
- Please indicate all clinical symptoms related to TB and for how long they have been present, several answers are possible.
- For all patients please answer question 5. If the patient has initiated / restarted / changed cART regimen for other reasons than toxicity AND either experienced worsening of TB disease diagnosed prior to initiation of cART or has been diagnosed with TB after cART has been initiated, please fill out a separate IRIS form.
- Information regarding diagnostic procedures for TB is requested in section C1. Please indicate all tests which were performed by indicating a number for the type of test (left column) and a letter for the type of specimen used (right column) If biopsy was taken (specimen ID E), please specify the tissue. Please indicate all tests that were performed, irrespectively of results available. Insert the date when the specimen was obtained from the patient (not the date of result).
- Clinical presentation of current TB disease should be completed in section C2. Several answers are possible, if patients e.g. have both pulmonary and extrapulmonary locations.

#### **6. Section D: Information regarding treatment of current TB and resistance testing:**

- All drugs used for the current TB disease should be filled out, including vitamin B6 and steroids. Furthermore, information on resistance testing is required. If standard treatment has not been given, please indicate why.
- The time when a drug is first started, i.e. “*date of start*”, should be completed for all drugs used. If a patient has discontinued a drug you should indicate “*date of stopping*” and “*reason for discontinuation*”. If the patient has received the drug in several intervals, provide all available “*date(s) of start*” and “*date(s) of stopping*”. For drug names please use abbreviations provided on the top of the page
- Please indicate daily doses and frequency of drugs intake. Please see codes for frequency on the top of the page.
- Please indicate reasons of discontinuation by using codes on the top of the page. If patient has completed the full course of TB treatment as prescribed, please indicate the reason for discontinuation as 93.1 “*Completed recommended duration of therapy*”
- If resistance test was not performed, please indicate reasons for that by answering question 3
- If standard treatment (containing RHZ) has not been given, please indicate why by answering question 4

#### **7. Section E: Information on clinical outcome for current TB diagnosis:**

- Clinical outcome of current TB diagnosis should be filled out. Definitions of clinical outcome are listed on page 3 (please use these definitions for correct outcome).

#### **8. Section F: Information on patients who died:**

- For patients who have died, please fill out whether an autopsy was performed. Please indicate what was the presumed cause of death. A “Cause of Death” (=CoDe) form should be filled out for all patients who died.

## **HIV/TB Co-infection project**

### **Instructions for TB form**

#### **List of definitions of TB diagnoses and treatment outcomes<sup>1,2</sup>**

##### ***TB diagnoses***

A "**definite**" case of tuberculosis is a case with culture confirmed infection with *M. tuberculosis* complex (if routine culturing of specimens from all cases is not performed, a patient with sputum smear examinations positive for acid-fast bacilli (AFB) is also considered to be a "definite" case).

**Pulmonary:** Pulmonary is defined as tuberculosis of the lung parenchyma and the tracheobronchial tree only. Extrapulmonary tuberculosis is then defined as tuberculosis affecting any site other than pulmonary as defined.

**Pleural:** Pleural tuberculosis is defined here as extrapulmonary tuberculosis and is tuberculous pleurisy only, with or without effusion.

**Lymphatic:** Lymphatic tuberculosis includes tuberculosis involving the lymphatic system. Because of the intrathoracic manifestations of tuberculosis in patients with human immunodeficiency virus (HIV) infection, lymphatic tuberculosis is preferably further differentiated into intrathoracic and extrathoracic lymphatic tuberculosis: 1) Intrathoracic - intrathoracic lymphatic tuberculosis; and 2) Extrathoracic - lymphatic tuberculosis other than intrathoracic lymphatic tuberculosis.

**Bone joint:** Tuberculosis of the bones and/or joints should be subdivided into: 1) tuberculosis of the spine; and 2) tuberculosis of bones/joints other than spine.

**Central nervous system (CNS):** Tuberculosis of the central nervous system should be subdivided into: 1) tuberculous meningitis; and 2) tuberculosis of the CNS other than meningitis.

**Genitourinary.** Tuberculosis of the genitourinary system, including tuberculosis of kidney, ureter, bladder, and male and female genital tract.

**Peritoneal/digestive tract:** Peritoneal/digestive tract tuberculosis includes tuberculosis of the peritoneum with or without ascites and tuberculosis of the digestive tract.

**Disseminated:** Disseminated tuberculosis includes tuberculosis of more than two organ systems or miliary tuberculosis. If one of the affected sites is the lung parenchyma, the case should be classified as having both pulmonary and disseminated tuberculosis. Miliary tuberculosis, *e.g.* is thus classified as pulmonary and disseminated.

Where *M. tuberculosis* complex has been isolated from blood, the disease site should be designated "disseminated".

##### ***Treatment outcomes***

**Cure:** A patient is considered cured if he or she has completed a full course of anti-TB therapy and a) if the diagnosis was confirmed by culture, and conversion (culture negative) has been documented (at least on one occasion) during the continuation phase; or b) if the diagnosis was based on microscopy, there is documented evidence of two negative sputum smears during the continuation phase, one of which must be at the end of treatment. Applicable only for **pulmonary TB**.

**Treatment completed:** A patient who was notified as a definite case is defined as having completed treatment if the course of treatment prescribed was completed and if the patient was officially discharged by the attending physician, but in whom a) when the diagnosis was confirmed by culture, no bacteriological conversion has been documented, or b) when the diagnosis was based on microscopy, no smear result is available at the end of treatment.

**Treatment failure:** A patient, who fails to achieve bacteriological conversion within 5 months after the start of treatment or, after previous conversion, becomes sputum smear or culture positive again, and in whom the first-line treatment is replaced by second-line treatment, should be considered a failure case.

**Death:** A patient who died of any cause during the course of treatment is recorded under death.

**Treatment interrupted .** If the patient interrupts treatment for any reason, this is recorded as treatment interrupted. To be classified as such, interruption of treatment should be for >2 months, noncompletion of

## **HIV/TB Co-infection project**

### **Instructions for TB form**

treatment within 9 months if placed on a 6 month regimen or within 12 months for an 8 or 9 month regimen, or if the drug intake was <80% of the prescribed dose. Prolonged interruption of treatment, caused by serious adverse effects to the drugs, is also recorded under this heading.

**Transfer out:** Some patients may continue treatment at another treatment centre during the course of treatment. Where it is known that the patient moved, but no additional information is available, this should be recorded as transfer out.

### **Immune Reconstitution Inflammatory Syndrome (IRIS)**

**For details, please see instructions for specific IRIS form**

#### **IRIS induced by antiretroviral therapy in case of adequately treated case of tuberculosis**

1. The patient had a diagnosis of tuberculosis prior to cART initiation. This case has been (or is still) adequately treated, and
2. Symptoms consistent with an infectious/inflammatory condition appearing within three months of a new antiretroviral therapy (initiation/ reintroduction/ change of cART regimen), and
3. These symptoms cannot be explained by a newly acquired infection, nor by the expected clinical course of a previously recognized infectious agent, nor by side effects of therapy.

The date of IRIS is greater than the date of TB diagnosis (NEW-date).

#### **Other disease of interest**

1. Symptoms consistent with an infectious/inflammatory condition appear within three months of a newly started antiretroviral therapy (initiation/ reintroduction/ change of cART regimen), and
2. Symptoms can be attributed to a new opportunistic disease and, according to the treating physician, can not be explained by a newly acquired infection but by unmasking of a subclinical opportunistic disease and can not be explained by side effects of therapy.

The date of IRIS is equal to the date of TB diagnosis (NEW-date).

Copenhagen HIV Programme,  
January 2011

#### **Reference List**

1. Rieder, H. L. *et al.* Surveillance of tuberculosis in Europe. Working Group of the World Health Organization (WHO) and the European Region of the International Union Against Tuberculosis and Lung Disease (IUATLD) for uniform reporting on tuberculosis cases. *Eur Respir J* **9**, 1097-1104 (1996).
2. Veen, J. *et al.* Standardized tuberculosis treatment outcome monitoring in Europe. Recommendations of a Working Group of the World Health Organization (WHO) and the European Region of the International Union Against Tuberculosis and Lung Disease (IUATLD) for uniform reporting by cohort analysis of treatment outcome in tuberculosis patients. *Eur Respir J* **12**, 505-510 (1998).